**Analysis:**

The earnings call for Amgen Inc. revealed a solid performance in Q3 2021, with year-over-year revenue growth of 4% and EPS growth of 11%. The company highlighted strong volume growth for key products such as Prolia, EVENITY, Repatha, and Aimovig. Management also provided updates on the pipeline, including the launch of LUMAKRAS and the expected launch of Tezepelumab. However, the call also included discussions about pricing pressure and competition, as well as the potential impact of drug pricing reform in Washington. The overall tone was positive, with management emphasizing the company's strong pipeline and execution.

**Conclusion:**

The short-term impact on Amgen's stock is likely to be positive, given the strong Q3 results and the company's optimistic outlook for the future. However, the stock may face some volatility due to the uncertainty surrounding drug pricing reform and the potential impact of competition in the pipeline. Overall, the stock is expected to have a **1** rating for the short-term (1â€“2 weeks) impact.